Telbermin
From PeptidePlaza, the free peptide reference · Entry #1230 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Telbermin is a metabolic research peptide. Telbermin is a vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist currently in Phase 2 clinical trials.
Telbermin functions as an agonist for vascular endothelial growth factor receptor 1 (Flt-1) and vascular endothelial growth factor receptor 2 (KDR). It is being investigated for its potential therapeutic applications, with clinical trials reaching Phase 2 for Diabetic Foot and Phase 1 for Amyotrophic Lateral Sclerosis. Research has explored its safety in topical applications for chronic neuropathic diabetic foot ulcers and the broader effects of VEGF stimulation in diabetic foot ulcers.
1 Mechanism of action
Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist (agonist)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diabetic Foot
- Amyotrophic Lateral Sclerosis
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (2)
- Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers
Journal of wound care (2008) · RCT - The effect of VEGF stimulation in diabetic foot ulcers: A systematic review
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (2024) · Systematic Review
5 Safety and risk profile
5.1 Regulatory status
Telbermin is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Telbermin?
- Telbermin is a compound classified as a vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist. It is currently undergoing clinical investigation for its therapeutic potential.
- What is Telbermin used for?
- Telbermin is being studied for its potential use in treating Diabetic Foot, where it has reached Phase 2 clinical trials, and Amyotrophic Lateral Sclerosis, which is in Phase 1 trials.
- How does Telbermin work?
- Telbermin acts as an agonist for vascular endothelial growth factor receptor 1 (Flt-1) and vascular endothelial growth factor receptor 2 (KDR). This mechanism involves stimulating these receptors.
- What is the regulatory status of Telbermin?
- Telbermin is currently in Phase 2 clinical development. It has reached Phase 2 for Diabetic Foot and Phase 1 for Amyotrophic Lateral Sclerosis.
7 References
- Telbermin — molecule record ChEMBL. View source
- Telbermin — published literature (2 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Telbermin.
Shares vascular and endothelial pharmacology
Conbercept is a vascular endothelial growth factor (VEGF) inhibitor, primarily studied for ophthalmic conditions.
Shares growth and factor pharmacology
Becaplermin is a recombinant human platelet-derived growth factor, functioning as a platelet-derived growth factor receptor agonist. It is FDA-approved for the treatment of lower extremity diabetic neuropathic ulcers.
Also metabolic
A 16-amino acid peptide encoded within the mitochondrial genome — a newly discovered class of signaling molecule. Regulates metabolic homeostasis via AMPK and FOXO1 pathways.
Shares growth and factor pharmacology
Trafermin is an FDA-approved fibroblast growth factor receptor 2 agonist. It is studied for its role in tissue repair and regeneration.
Shares growth and factor pharmacology
An angiotensin IV derivative reported to be orders of magnitude more potent than BDNF at driving synaptogenesis. Its mechanism runs through c-Met — the same receptor that drives many cancers.
Also metabolic
A modified C-terminal fragment of human growth hormone (amino acids 177-191) with a tyrosine substitution. Studied primarily for its lipolytic (fat-burning) effects without the growth-promoting activity of full-length hGH.